By Small Pharma Analyst:Vertex (VRTX) is a 25-year old biopharma company that has had more than its share of ups and downs over the years - and yet another company-defining event is just around the corner.
Robert Weinstein submits:
The Way means inducing the people to have the same aim as the leadership, so that they will share death and share life, without fear of danger. -- Sun Tsu, The Art of War.
Vertex Pharmaceuticals Incorporated (VRTX) of Cambridge, MA was up strongly today to close at $49.95 a share.
Bert Wilkison submits:On 04/07/11, Vertex Pharmaceuticals (VRTX) made headlines when it announced that one of its long time collaborators, Cystic Fibrosis Foundation Therapeutics, agreed to provide up to $75M over the next five years to support research and development for some of Vertex's early stag
By Brian L. Wilson:Anyone who was watching Vertex Pharmaceuticals (VRTX) yesterday (October 11th, 2012) probably noticed the huge ~5% drop that was followed with an immediate reversal and subsequent decline. Vertex is normally a very calm and slow-moving stock, so any VRTX investors caught off guard may have added to the volatility with reactionary decisions.
By Stock Croc:If I were only able to give one piece of investment advice right now, it would be to buy Vertex Pharmaceuticals (VRTX). Though there are companies out there poised to make a big splash with upcoming products, and there are lower priced stocks available that might result in a bigger profit, I would still stick with Vertex.
By Scott Matusow:Vertex Pharmaceuticals (VRTX) yesterday received approval from The U.S. Food and Drug Administration for their drug Kalydeco, the first therapeutic drug to treat an underlying cause of cystic fibrosis. Kaydeco targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.